Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Exelixis (Nasdaq: EXEL ) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Exelixis and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||San Francisco (1994)|
|Market Cap||$718.4 million|
|Trailing-12-Month Revenue||$247.9 million|
|Management||Co-Founder/Chairman Dr. Stelios Papadopoulos
President/CEO Dr. Michael Morrissey
|Trailing-12-Month Return on Capital||25.6%|
|Cash/Debt||$207.0 million / $182.7 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 96% of the 2,644 members who have rated Exelixis believe the stock will outperform the S&P 500 going forward.
An extremely large combined dilutive and debt financing seems to have scared the pants off Exelixis traders and killed a burgeoning run-up into the cabozantinib PDUFA for medullary thyroid carcinoma in 11/29/12. The financing scares me too and I'm dubious about the long-term commercial prospects of cabozantinib, but the run-up has been very strong in the biopharma bull market of 2012 and I'll take my chances against the forces of dilution.
If you want market-thumping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Exelixis may not be your top choice.
We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit From the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.